Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Smith & Nephew plc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.27, while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while YieldMax AMZN Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| AMZY | SNN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $38.70 |
52-Week Low | $9.98 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.24, down 3.27% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions from YieldMax ETFs, though analyst reports express concerns about NAV erosion despite the high yield strategy.
The outlook for AMZY is mixed; the bullish technical trend and high dividend yield present income opportunities, but fundamental risks include potential NAV erosion and underperformance relative to Amazon. Investors should weigh the attractive weekly distributions against the sustainability of the option income strategy and amplified downside risks highlighted by analysts.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
